Citius Oncology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CTOR research report →
Range $6 – $6
Price Chart
About the company
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies.
- CEO
- Leonard L. Mazur
- IPO
- 2022
- Employees
- 285
- HQ
- Cranford, NY, US
Get TickerSpark's AI analysis on CTOR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $46.82M
- P/E
- -1.18
- Fwd P/E
- 1.94
- PEG
- 0.03
- P/S
- 7.40
- P/B
- 1.51
- EV/EBITDA
- -1.07
- Div Yield
- 0.00%
- Gross Margin
- 53.13%
- Op Margin
- -665.63%
- Net Margin
- -648.32%
- ROE
- -102.98%
- ROIC
- -88.72%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-23,522,750
- Net Income
- $-24,761,369-17.1%
- EPS
- $-0.34-13.3%
- OCF Growth
- -4446.6%
- FCF Growth
- -4446.7%
- 52W High
- $1.83
- 52W Low
- $0.49
- 50D MA
- $0.75
- 200D MA
- $0.79
- Beta
- 3.58
- RSI (14)
- 37
- Avg Volume
- 114.02K
No earnings-call transcripts are available for CTOR yet.
- Free Float
- 19.1%
- Shares Outstanding
- 92.98M
- Float Shares
- 17.72M
of shares held by institutions
20 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Armistice Capital, LLC | 8.34M | ▼ 366.25K |
| Bank Of America Corp | 3.84M | ▲ 15 |
| Vanguard Group Inc | 597.00K | ▲ 416.83K |
| Vanguard Capital Management LLC | 546.33K | 0 |
| Geode Capital Management, LLC | 281.93K | ▲ 36.52K |
| Vanguard Fiduciary Trust Co | 175.10K | ▲ 53.19K |
| Citadel Advisors LLC | 125.82K | ▲ 35.24K |
| Pfs Signature Wealth LLC | 107.42K | ▲ 107.42K |
| Northern Trust Corp | 45.75K | 0 |
| State Street Corp | 42.90K | 0 |
| Hrt Financial LP | 31.23K | ▲ 31.23K |
| Private Advisor Group, LLC | 25.00K | ▲ 25.00K |
Held by 21 ETFs
Biggest fund positions in CTOR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 12, 26 | Dutia Suren G | other | 125,000 |
| Nov 12, 26 | Smith Robert Joseph | other | 125,000 |
| Nov 12, 26 | Peri Jonathan | other | 125,000 |
| Nov 12, 26 | Mayersohn Joel David | other | 125,000 |
| Nov 12, 26 | Holuka Eugene Myron | other | 125,000 |
| Nov 12, 26 | MCGRATH DENNIS M | other | 125,000 |
| Nov 12, 26 | Webb Carol | other | 125,000 |
| Nov 9, 26 | HOLUBIAK MYRON Z | other | 300,000 |
| Nov 9, 26 | HOLUBIAK MYRON Z | other | 50,000 |
| Nov 9, 26 | Bartushak Jaime | other | 400,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CTOR coverage
Recent articles, reports, and earnings notes.
No research on CTOR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CTOR report →Citius Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
prnewswire.com · Nov 11
Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe
prnewswire.com · Nov 4
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
gurufocus.com · Oct 26
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
prnewswire.com · Oct 26
Citius Pharmaceuticals to Participate in October 2026 Investor Conferences
prnewswire.com · Oct 12
Citius Pharmaceuticals to Participate in September 2026 Investor Conferences
prnewswire.com · Sep 3
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
prnewswire.com · Aug 14
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
prnewswire.com · Aug 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.